How Much Chemotherapy Is Required to Optimise Long-term Outcomes in Clinical Stage 2 Seminoma?

Sigg, Silvan; Heidenreich, Axel; Papachristofilou, Alexandros; Fankhauser, Christian Daniel

Sigg, Silvan; Heidenreich, Axel; Papachristofilou, Alexandros; Fankhauser, Christian Daniel.

Afiliação

Sigg S; Department of Urology, Luzerner Kantonsspital, University of Lucerne, Lucerne, Switzerland.
Heidenreich A; Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Papachristofilou A; Department of Radiation Oncology, University Hospital Basel, Basel, Switzerland.
Fankhauser CD; Department of Urology, Luzerner Kantonsspital, University of Lucerne, Lucerne, Switzerland. Electronic address: cdfankhauser@gmail.com.

Eur Urol ; 84(1): 32-35, 2023 07.

Article em En | MEDLINE | ID: mdl-36609008

Assuntos

Seminoma; Neoplasias Testiculares; Masculino; Humanos; Seminoma/patologia; Neoplasias Testiculares/patologia; Terapia Combinada; Estadiamento de Neoplasias; Orquiectomia; Radioterapia Adjuvante; Quimioterapia Adjuvante; Estudos Retrospectivos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Testiculares / Seminoma Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google